Table 1. The analytical results of correlations between p53 mutations and p53 overexpression.
| Reference | Country | Potential mutagen | Sample size | TP | FP | FN | TN | IHC cut-off/Exon | Analytical method (antibody/gene) | QUADAS-2 |
|---|---|---|---|---|---|---|---|---|---|---|
| An et al. 2001 [35] | Japan | HCV | 11 of 41 | 1 | 7 | 0 | 3 | NA/exons 5–8 | IHC (DO-7)/PCR-DNA sequencing | 11 |
| Andersson et al. 1995 [33] | Denmark | alpha-particles | 18 of 36 | 0 | 2 | 1 | 15 | 1%/exons 5,7,8 | IHC (DO-7)/PCR-DGGE, DNA sequencing | 9 |
| Anzola et al. 2004 [15] | Spain | HCV, alcohol | 117 from 78 | 4 | 23 | 8 | 82 | 10%/exons 4–8 | IHC (DO-7)/PCR-SSCP, DNA sequencing | 11 |
| Boix-Ferrero et al. 1999 [20] | Spain | HCV, alcohol | 70 of 129 | 1 | 13 | 1 | 55 | 10%/exons 5–8 | IHC (Bp 53–11)/PCR-DNA sequencing | 11 |
| Bourdon et al. 1995 [14] | France | HBV | 20 | 5 | 5 | 1 | 9 | NA/exons 2–11 | IHC (PAb1801)/PCR-DNA sequencing | 10 |
| Challen et al. 1992 [22] | UK | –* | 19 | 1 | 0 | 1 | 17 | 10%/exons 5–8 | IHC (–)/PCR-DNA sequencing | 9 |
| Chen et al. 2003 [43] | China | HBV | 33 | 16 | 5 | 0 | 12 | NA/exons 2–8 | IHC (Santa)/PCR-DNA sequencing | 10 |
| Cheung et al. 2006 [4] | China | HBV | 55 | 17 | 11 | 9 | 18 | NA/exons 4–9 | IHC (DO-7)/PCR-DNA sequencing | 11 |
| De Benedetti et al. 1996 [41] | USA | Contraceptive | 10 of 11 | 1 | 2 | 0 | 7 | 1%/exons 4–9 | IHC (–)/PCR-DNA sequencing | 9 |
| Greenblatt et al. 1997 [29] | China | HBV | 16 | 1 | 5 | 2 | 8 | 1%/exons 4–8 | IHC (CM-1)/PCR-DNA sequencing | 9 |
| Gross-Goupil et al. 2003 [16] | France | HBV, HCV | 18 | 0 | 4 | 2 | 12 | 10%/exons 2–11 | IHC (DO-7)/PCR-DNA sequencing | 10 |
| Hsia et al. 2000 [24] | China | –* | 28 | 16 | 3 | 1 | 8 | 10%/exons 5–8 | IHC (–)/PCR-DNA sequencing | 9 |
| Hsu et al. 1993 [26] | China | HBV, HCV | 78 of 184 | 30 | 9 | 10 | 29 | 10%/exons 2–11 | IHC (DO-7)/PCR-SSCP, DNA sequencing | 9 |
| Jablkowski et al. 2005 [9] | Poland | HBV | 9 of 20 | 4 | 1 | 1 | 3 | 50%/exons 5–8 | IHC (DO-7)/PCR-DNA sequencing | 10 |
| Kang et al. 1998 [39] | Korea | HBV | 8 of 13 | 2 | 2 | 0 | 4 | 20%/exons 5–8 | IHC (DO-7)/PCR-SSCP, DNA sequencing | 9 |
| Kubicka et al. 1995 [32] | Germany | HBV | 20 | 1 | 0 | 1 | 18 | 30%/exons 5–8 | IHC (PAb1801/PAb240) /PCR-DNA sequencing | 9 |
| Lee et al. 2002 [25] | Korea | HBV | 36 from 34 | 6 | 9 | 1 | 20 | 5%/exons 4–10 | IHC (BP53-12)/PCR-SSCP, DNA sequencing | 10 |
| Lunn et al. 1997 [42] | China | HBV, AFB1 | 105 | 22 | 13 | 7 | 63 | 5%/exons 5–9 | IHC (DO-1/Ab-6)/PCR-SSCP, DNA sequencing | 9 |
| Luo et al. 2001 [45] | China | – | 21 | 6 | 5 | 3 | 7 | 10%/exons 5–8 | IHC (DO-7)/PCR-SSCP | 10 |
| Mitsumoto et al. 2004 [31] | Japan | HCV | 50 | 13 | 1 | 8 | 28 | 10%/– | IHC (DO-7)/Yeast p53 Functional Assay, DNA sequencing | 9 |
| Mohamed et al. 2008 [5] | Egypt | HBV, HCV | 30 | 7 | 9 | 4 | 10 | 10%/exons 5–8 | IHC (DO-7)/PCR-SSCP, DNA sequencing | 11 |
| Okada et al. 2003 [27] | Japan | HCV | 10 of 22 | 5 | 1 | 0 | 4 | 10%/exons 5–9 | IHC (DO-7)/PCR-DNA sequencing | 10 |
| Peng et al. 1998 [23] | China | – | 70 | 21 | 9 | 2 | 38 | 5%/exon 7 | IHC (DO-7)/RFLP | 9 |
| Qi et al. 2015 [8] | China | HBV, AFB1 | 397 | 208 | 58 | 15 | 116 | 25%/exons 1–11 | IHC (Abcam)/PCR-DNA sequencing | 11 |
| Qin et al. 1998 [38] | China | HBV | 26 of 31 | 5 | 1 | 1 | 19 | NA/exons 5–9 | IHC (PAb1801/PAb240) /PCR-DNA sequencing | 9 |
| Rashid et al. 1999 [10] | China | HBV | 24 | 10 | 3 | 2 | 9 | NA/exons 2–9 | IHC (DO-7)/PCR-DNA sequencing | 11 |
| Ryder et al. 1996 [37] | Germany | HBV, HCV | 37 of 38 | 15 | 3 | 2 | 17 | 80%/exons 5–8 | IHC (DO-1)/PCR-SSCP, DNA sequencing | 10 |
| Sanefuji et al. 2010 [34] | Japan | HCV | 79 of 82 | 13 | 34 | 0 | 32 | 10%/exons 5–8 | IHC (DO-7)/PCR-DNA sequencing | 11 |
| Shieh et al. 1993 [36] | USA | HBV, HCV | 18 | 1 | 0 | 0 | 17 | NA/exon 7 | IHC (PAb1801)/PCR-DNA sequencing | 9 |
| Soini et al. 1996 [21] | Mexico | AFB1 | 14 of 21 | 2 | 4 | 1 | 7 | 1%/exon 7 | IHC (CM-1)/PCR-DNA sequencing | 9 |
| Stern et al. 2001 [28] | China | HBV, AFB1 | 48 of 64 | 15 | 15 | 3 | 15 | NA/exon 7 | IHC (CM-1)/PCR-DNA sequencing | 10 |
| Szymańska et al. 2004 [11] | Gambia | HBV | 28 of 29 | 9 | 4 | 5 | 10 | 10%/exons 5–8 | IHC (CM-1)/PCR-RFLP, DNA sequencing/SOMA | 9 |
| Volkmann et al. 2001 [30] | Germany | HBV, HCV | 39 | 8 | 3 | 3 | 25 | 10%/exons 5–9 | IHC (DO-1)/PCR-SSCP, DNA sequencing | 10 |
| Zekri et al. 2006 [40] | Egypt | HCV | 25 | 7 | 6 | 3 | 9 | 10%/exons 5–8 | IHC (DO-7)/PCR-SSCP, DNA sequencing | 9 |
| Zhang et al. 2006 [12] | China | HBV, AFB1 | 40 | 9 | 5 | 2 | 24 | 5%/exons 5–8 | IHC (DO-7)/PCR-DNA sequencing | 10 |
| Zhou et al. 1997 [44] | China | HBV | 32 | 2 | 6 | 0 | 24 | NA/exon 7 | IHC (DO-1/Ab-6)/PCR-RFLP | 9 |
HBV/HCV: hepatitis B/C virus; AFB1: aflatoxin B1; IHC: immunohistochemistry; PCR: polymerase chain reaction; SSCP: single-strand conformation polymorphism; RFLP: restriction fragment length polymorphism; SOMA: short oligonucleotide mass spectrometry analysis; DGGE: denaturing gradient gel electrophoresis; QUADAS, Quality Assessment of Diagnostic accuracy studies.